Neurodegeneration in multiple sclerosis: Relationship to neurological disability

Neuroscientist

Volumn 5, Issue 1, 1999, Pages 48-57

  Trapp, Bruce D ^a   Ransohoff, Richard M ^a   Fisher, Elizabeth ^a   Rudick, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Axonal degeneration; Brain atrophy; Demyelination; Multiple; Neuroprotection; Sclerosis

Indexed keywords

BRAIN ATROPHY; BRAIN PROTECTION; DEMYELINATING DISEASE; DISABILITY; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; RELAPSE; REVIEW;

EID: 0032915309     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849900500107     Document Type: Review

References (62)

1. Chelmicka-Schorr E, Araason BG. Nervous system-immune system interactions and their role in multiple sclerosis. Ann Neurol 1994;36:S29-S32.
2. Ludwin SK. Central nervous system remyelination: studies in chronically damaged tissue. Ann Neurol 1994;36:S143-S145.
3. Charcot M. Histologie de la sclerose en plaques. Gaz Hosp 1868; 141:554-555, 557-558.
4. Putnam TJ. Studies in multiple sclerosis. Arch Neurol Psych 1936; 35:1289-1308.
5. Greenfield JG, King LS. Observations on the histopathology of the cerebral lesions in disseminated sclerosis. Brain 1936;59:445-458.
6. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399.
7. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, et al. Precursor of amyloid protein in Alzheimer disease undergoes fast antcrograde axonal transport. Proc Natl Acad Sei U S A 1990;87:1561-1565.
8. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in multiple sclerosis lesions. N Engl J Med 1998;338:278-285.
9. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and rumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-954.
10. B5 L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994;36:778-786.
11. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives (invited review). Brain 1997; 120:865-916.
12. McKhann GM, Comblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, et al. Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342.
13. Ho TW, McKhann GM, Griffin JW. Human autoimmune neuropathies. Annu Rev Neurosci 1998;21:187-226.
14. Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996;25:33-51.
15. Hafer-Macko C, Hsieh S-T, Li CY, Ho TW, Sheikh KA. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-644.
16. Sanchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 1996;16:5095-5105.
17. Hsieh ST, Kidd GJ, Crawford TO, Xu Z, Lin WM, Trapp BD, et al. Regional modulation of neurofilament organization by myelination in normal axons. J Neurosci 1994;14:6392-6401.
18. deWaegh SM, Lee VM-Y, Brady ST. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 1992;68:451-463.
19. Giese KP, Martini R, Lemke G, Soriano P, Schachner M. Mouse Po gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 1992;71:565-576.
20. Bergoffen J, Scherer SS, Wang S, Scott MO, Bone LJ, Paul DL, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993;262:2039-2042.
21. Anzini P, Neuberg DH-H, Schachner M, Nelles E, Willecke K, Zielasek J, et al. Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci 1997; 17:4545-4551.
22. Yin X, Crawford TO, Griffin JW, Tu Ph, Lee VM, Li C, et al. Myelin-associate glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 1998;18:1953-1962.
23. Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998;280:1610-1613.
24. Salzer JL, Holmes WP, Colman DR. The amino acid sequences of the myelin-associated glycoproteins: homology to the immunoglobulin gene superfamily. J Cell Biol 1987; 104:957-965.
25. Arquint M, Roder J, Chia LS, Down J, Wilkinson D, Bayley H, et al. Molecular cloning and primary structure of myelin-associated glycoproteins. Proc Natl Acad Sei U S A 1987;84:600-604.
26. Lai C, Brow MA, Nave KA, Noronha AB, Quartes RH, Bloom FE, et al. Two forms of lB236/myelin-associated glycoprotein (MAG), a cell adhesion molecule for postnatal neural development, are produced by alternative splicing. Proc Natl Acad Sei USA 1987;84:4337-4341.
27. Sternberger NH, Quarks RH, Itoyama Y, Webster HD. Myelin-associated glycoprotein demonstrated immunocytochemically in myelin and myelin-forming cells of developing rats. Proc Natl Acad Sei U S A 1979;76:1510-1514.
28. Trapp BD, Andrews SB, Cootauco C, Quarles RH. The myelinassociated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes. J Cell Biol 1989; 109:2417-2426.
29. Li C, Tropak MB, Gerlai R, Clapoff S, Abramow-Newerly W, Trapp B, et al. Myelination in the absence of myelin-associated glycoprotein. Nature 1994;369:747-750.
30. Montag D, Giese KP, Bartsch U, Martini R, Lang Y, Bluthmann H, et al. Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron 1994;13:229-246.
31. McKerracher L, David S, Jackson DL, Kottis V, Dünn RJ, Braun PE. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neunte growth. Neuron 1994;13:805-811.
32. Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, Filbin MT. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 1994;13:757-767.
33. Li M, Shibata A, Li C, Braun PE, McKerracher L, Roder J, et al. Myelin-associated glycoprotein inhibits neurite/axon growth and causes growth cone collapse. J Neurosci Res 1996;46:404-414.
34. Pant HC, Veeranna. Neurofilament phosphorylation. Biochem Cell Biol 1995;73:575-592.
35. Hodes ME, Dlouhy SR. The proteolipid protein gene: double, double, ... and trouble. Am J Hum Genet 1996;59:12-15.
36. Seitelberger F. Neuropathology and genetics of Pelizaeus-Merzbacher disease. Brain Pathol 1995;5:267-273.
37. Griffiths IR, Schneider A, Anderson J, Nave K-A. Transgenic and natural mouse models of proteolipid protein (PLP) related dysmyelination and demyelination. Brain Pathol 1995;5:275-281.
38. Duncan ID, Hammang JP, Trapp BD. Abnormal compact myelin in the myelin-deficient rat: Absence of proteolipid protein correlates with a defect in the intraperiod line. Proc Natl Acad Sei USA 1988;84:6287-6291.
39. Helynck G, Luu B, Nussbaum J-L, Picken D, Skalidis G, Trifilieff E, et al. Brain proteolipids: Isolation, purification and effect on ionic permeability of membranes. Eur J Biochem 1983;133:689-695.
40. Kitagawa K, Sinoway MP, Yang C, Gould RM, Colman DR. A proteolipid protein gene family: expression in sharks and rays and possible evolution from an ancestral gene encoding a pore-forming polypeptide. Neuron 1993; 11:433-448.
41. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.
42. McFarland HF, Stone LA, Calabresi PA, Maloni H, Bash CN,. Frank JA. MRI studies of multiple sclerosis: implications for the natural history of the diseases and for monitoring effectiveness of experimental therapies. Mult Scier 1996;2:198-205.
43. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, et al. Magnetic resonance studies of intramuscular interferon beta-la for relapsing multiple splerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87.
44. Moffett JR, Namboodiri MAA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991 ;2:131-134.
45. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetylaspartate with monoclonal antibodies. Neuroscience 1991;45:37-45.
46. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76-82.
47. Narayanan S, Fu L, Pioro E, De Stefano N, Collins DL, Francis GS, et al. Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385-391.
48. De Stefano N, Matthews PM, Narayanan S, Francis GS, Antel JP, Arnold DL. Axonal dysfunction and disabililty in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 1997;49:1138-1141.
49. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, et ai. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;! 19:2009-2019.
50. Matthews PM, Pioro E, Narayanan S, De Stefano N, Fu L, Francis G, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996; 119:715-722.
51. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;! 17:49-58.
52. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995; 34:721-727.
53. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-909.
54. Kimura H, Grossman RI, Lenkinski RE, Gonzalez-Scarano F. Proton MR spectroscopy and magnetization transfer ratio in multiple sclerosis: Correlative findings of active versus irreversible plaque disease. AJNR Am J Neuroradiol 1996;17:1539-1547.
55. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121:103-113.
56. Simon JH, Schiffer RB, Rudick RA, Hemdon RM. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. AJNR Am J Neuroradiol 1987;8:599-604.
57. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;! 19:701-708.
58. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;! 18:1583-1592.
59. Simon JH, Jacobs LD, Campion M, Rudick RA. A longitudinal study of brain atrophy in relapsing MS [abstract]. Neurology 1998; in press.
60. LaRocca NG. National Multiple Sclerosis Society Health Services Research Reports: Employment and Multiple Sclerosis. 1995;1-40.
61. Bradley WG. Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies. Muscle Nerve 1998; 10: 490-502.
62. Lloyd KG. CNS compensation to dopamine neuron loss in Parkinson's disease. Adv Exp Med Biol 1977;90:255-266.